Elevar Therapeutics
- Company typePrivate
- Founded2005
- HeadquartersSalt Lake City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Elevar Therapeutics firmographics
Firmographics- Name
- Elevar Therapeutics
- Website
- https://elevartherapeutics.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Elevar Therapeutics industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Digestive Oncology (GI Cancer Care) (HLAKAEAF)
Keywords
Where Elevar Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Elevar Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Drug Sales: Pre-revenue biopharmaceutical company expecting commercialization of lirafugratinib following FDA approval. The company is preparing for commercialization and allocating significant resources to regulatory approval and market preparation.
- Future Drug Combination Sales: Plan to resubmit drug application for rivoceranib and camrelizumab combination in January 2026 for hepatocellular carcinoma treatment following positive Phase 3 CARES-310 study results.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Elevar Therapeutics product offering
Product offeringCore offering
Elevar Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies for rare and underserved cancers. Its lead candidate, lirafugratinib, is an investigational FGFR2 inhibitor under FDA Priority Review for second-line treatment of cholangiocarcinoma with FGFR2 fusions or rearrangements (PDUFA date September 27, 2026). The company is also advancing the rivoceranib and camrelizumab combination (CARES-310) for unresectable hepatocellular carcinoma based on positive Phase 3 results.
Product overview
Elevar Therapeutics is a pharmaceutical/biotechnology company focused on developing cancer therapeutics. The company's core product portfolio includes lirafugratinib, an investigational FGFR2 inhibitor currently under FDA Priority Review for second-line cholangiocarcinoma treatment, and the rivoceranib/camrelizumab combination therapy (CARES-310) for unresectable hepatocellular carcinoma. Elevar operates as a subsidiary of HLB, a Korean biotechnology firm, and is advancing clinical development across multiple cancer types.
Differentiator
Problem solved
Functional benefit
Products and services
- Lirafugratinib
- Rivoceranib + Camrelizumab Combination (CARES-310)
Quantifiable outcome
- 46.5% confirmed objective response rate in patients with FGFR2 fusion/rearrangement cholangiocarcinoma (ReFocus Phase 1/2 trial)
- +3 more outcomes
Companies that use Elevar Therapeutics
Customer profileSegments3 records
Ideal customer profiles1 record
Elevar Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Elevar Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Samsung Medical CentercoreSamsung Medical Center in Seoul is a clinical trial site for the ReFocus202 Phase 2 study evaluating lirafugratinib for non-cholangiocarcinoma solid tumors with FGFR2 fusion or rearrangement.
- Moffitt Cancer CentercoreMoffitt Cancer Center in Tampa is a clinical trial site for the ReFocus202 Phase 2 study evaluating lirafugratinib for non-cholangiocarcinoma solid tumors with FGFR2 fusion or rearrangement.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
Elevar Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Roche / Genentech: Roche/Genentech markets atezolizumab + bevacizumab (Tecentriq + Avastin), the current standard of care in first-line uHCC. Comparable as the dominant incumbent whose immunotherapy combination defines the HCC treatment landscape.
- Exelixis: Exelixis markets cabozantinib (Cabometyx) in hepatocellular carcinoma, including settings where Elevar's rivoceranib+camrelizumab combination competes. Comparable as an established oncology company in the HCC competitive landscape.
- AstraZeneca: AstraZeneca markets the STRIDE regimen (durvalumab + tremelimumab) in uHCC, a direct competitive regimen to the CARES-310 combination. Comparable as a global oncology incumbent whose HCC franchise shapes the market Elevar is entering.
Direct peers
- Incyte Corporation: Incyte markets pemigatinib (Pemazyre), an FGFR inhibitor approved for FGFR2-fusion cholangiocarcinoma. It is the most directly comparable competitor in the same indication that Elevar's lirafugratinib targets, with established commercial infrastructure in second-line CCA.
- HUTCHMED: HUTCHMED is an Asia-headquartered biopharma developing oncology therapeutics, including surufatinib, with global commercialization strategy. Directly comparable to Elevar as an Asian-originated biopharma advancing innovative oncology drugs into the U.S. market.
- Taiho Oncology: Taiho Oncology markets futibatinib (Lytgobi), another FDA-approved FGFR inhibitor for FGFR2-fusion cholangiocarcinoma. Direct head-to-head competitor to lirafugratinib in the same second-line CCA indication.
Emerging players
- Erasca: Erasca is a clinical-stage precision oncology company with FGFR pathway programs. Comparable as a small-cap, kinase-inhibitor-focused oncology developer pursuing FGFR-driven cancers.
- Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company developing FGFR2-selective inhibitors. Comparable as a targeted-kinase-inhibitor oncology developer with overlapping FGFR2 biology.
- QED Therapeutics (BridgeBio): QED Therapeutics, a BridgeBio subsidiary, developed infigratinib, an earlier FGFR inhibitor in cholangiocarcinoma. Comparable as an FGFR-focused oncology developer with overlapping target indication.
Regional players
- Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty biopharma with a strong oncology and rare-disease commercial footprint in the U.S. and Europe. Comparable as a specialty/rare-disease commercial model against which Elevar's U.S. field-sales and specialty distribution strategy will be benchmarked.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Elevar Therapeutics social profiles
Digital presenceElevar Therapeutics compliance and trust
Trust signalCompliance3 records
Elevar Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elevar Therapeutics leadership team
Management profileNumber of profiles
Profiles13 records
Elevar Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elevar Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elevar Therapeutics
What does Elevar Therapeutics do?
Elevar Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies for rare and underserved cancers. Its lead candidate, lirafugratinib, is an investigational FGFR2 inhibitor under FDA Priority Review for second-line treatment of cholangiocarcinoma with FGFR2 fusions or rearrangements (PDUFA date September 27, 2026). The company is also advancing the rivoceranib and camrelizumab combination (CARES-310) for unresectable hepatocellular carcinoma based on positive Phase 3 results.
Is Elevar Therapeutics a public or private company?
Elevar Therapeutics is a private company. It is classified as corporate owned and is currently operating.
When was Elevar Therapeutics founded?
Elevar Therapeutics was founded in 2005. It employs 11 to 50 people.
Where is Elevar Therapeutics based?
Elevar Therapeutics is headquartered in Salt Lake City, United States, in the North America region.
How does Elevar Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Drug Sales are the primary driver. The others are future Drug Combination Sales.
Who are Elevar Therapeutics's main competitors?
Broad incumbents on record are Roche / Genentech, Exelixis and AstraZeneca. Direct peers are Incyte Corporation, HUTCHMED and Taiho Oncology. Emerging players are Erasca, Relay Therapeutics and QED Therapeutics (BridgeBio). Jazz Pharmaceuticals is listed as a regional player.
Does Elevar Therapeutics have an API?
No public API is recorded for Elevar Therapeutics.
What industry is Elevar Therapeutics in?
Elevar Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 3254 and its SIC code is 2834.